Yes, positive vote, but major KNOWN safety issues. For DVAX only speculative theories, the no vote was not sufficient info, and partially, if not mostly based on the GSK's consultant question about whether the analysis was complete. When the FDA spokesman said they're still working through it, it tipped the balance, even though FDA was convinced of safety. So for ISIS, in summary, they approved a drug with known significant safety issues, even though AEGR drug is already approved with very little safety concerns. Secondly, the no vote on DVAX, again was diversity and completion of analysis by FDA which occurred subsequent to Adcom. I like the odds, and put my chips down on DVAX. Good luck to you.